ANGLE plc (ANPCF) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of ANGLE plc $0.02, price $0.02, upside -23.6%, quality 31 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch ANGLE plc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally.
Show more
CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 system captures and harvests circulating tumour cells from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal circulating tumour cells; and CellKeep Slide, a CTC harvesting technology. In addition, the company offers laboratory services, including CTC enrichment and liquid biopsy analysis services; Portrait Flex, an immunofluorescence assay for the identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition; DNA damage response; Portrait PD-L1, evaluates CTCs; and custom CTC assays. CelLBxHealth plc has a strategic partnership with BioView Ltd to develop a human epidermal growth factor receptor 2 assay kit for breast cancer; and agreement with NuProbe USA, Inc. to use pan-cancer next generation sequencing (NGS) panel. The company also has a research collaboration with The Royal Marsden NHS Foundation Trust. The company was formerly known as ANGLE plc and changed its name to CelLBxHealth plc in October 2025. CelLBxHealth plc was founded in 1994 and is based in Guildford, the United Kingdom.
Stock analysis
ANGLE plc (ANPCF) currently trades at $0.0199, while our model-based Fair Value estimate is $0.0152, implying the stock looks roughly 30.9% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 91/100, which puts the evidence level at low.
Quality & growth
The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
ANGLE plc reported revenue of £2.9M in FY2024 versus £762K in FY2020, a compound +39.2%/yr. Reported net income was −£14.2M in FY2024.
Key figures
Market cap $38.7M · P/S ratio 14.8 · EPS (TTM) $−0.0600 · Return on equity −87.2% · Return on assets (EBIT) −49.3% · Operating margin −1,216% · Revenue (TTM) £2.6M · Revenue growth (YoY) −23.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).
What moves the price
The share trades about 58% below its 52-week high and 93% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −24%, ANPCF screens richer than that median.
Fair Value models
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+30.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+41.4%
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.8%
’11
’12
’13
’15
’16
’17
’18
’20
’21
’22
’23
’24
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,607.5% (2018) → −540.7% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2024 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 143 stocks
Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score34 · Bottom 25%
Fair Value upside−23.6% · Above median
Profitability
Return on assets−40.0% · Bottom 25%
Growth and dividend
Revenue growth−23.0% · Bottom 25%
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "ANGLE plc Fair Value". https://www.fairvalue-calculator.com/stock/ANPCF
Frequently asked questions
Is ANGLE plc (ANPCF) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.0152 versus a price of $0.0199, about −24% upside (overvalued).
What is the fair value of ANPCF?
Our model-based fair value for ANGLE plc is $0.0152 (as of Sep 23, 2026), built from audited fundamentals. The current price: $0.0199.
What is the quality score of ANPCF?
ANGLE plc has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ANGLE plc (ANPCF)?
Our model-based price target is the fair value of $0.0152 (as of Sep 23, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the ANGLE plc stock forecast for 2026?
Our models put fair value at $0.0152, about −24% upside versus a price of $0.0199 (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of ANGLE plc (ANPCF)?
ANGLE plc reported trailing-twelve-month revenue of about £2.6M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of ANGLE plc (ANPCF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ANGLE plc it is $0.0152 per share (as of Sep 23, 2026), against a price of $0.0199. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is ANGLE plc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, ANPCF trades above its calculated fair value: price $0.0199, fair value $0.0152, a gap of about −24% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ANPCF?
No. The price is what the market pays today ($0.0199); the fair value is what the company's own numbers justify ($0.0152). For ANGLE plc the two are $0.0047 per share apart. That gap is exactly why we show both numbers side by side.
How much is ANGLE plc worth?
The market values ANGLE plc at about $38.7M (market capitalisation, as of Sep 23, 2026). Per share that is $0.0199; our models calculate a fair value of $0.0152 per share.
How solid is the balance sheet of ANGLE plc (ANPCF)?
Balance-sheet figures for ANGLE plc (as of Sep 23, 2026): return on equity −87.2%. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is ANPCF from its 52-week high?
ANGLE plc trades at $0.0199, about 58% below its 52-week high of $0.0477 and 93% above the low of $0.0103 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0152 is for.
Which stocks are comparable to ANGLE plc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ANGLE plc stock attractive at the current price?
The data as of Sep 23, 2026: price $0.0199, calculated fair value $0.0152 (−24%), Quality Score 31/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ANPCF calculated?
We run ANGLE plc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0152, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9 % above its aggregate fair value. ANGLE plc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ANGLE plc (ANPCF)?
The closing price on Sep 25, 2026 was $0.0199. Our model-based fair value is $0.0152, about −24% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ANGLE plc right now?
Weak quality (31/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of ANGLE plc
How large is the market capitalisation of ANGLE plc (ANPCF)?
The market capitalisation of ANGLE plc is $38.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ANGLE plc (ANPCF)?
The price-to-sales ratio of ANGLE plc is 14.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of ANGLE plc (ANPCF)?
Earnings per share at ANGLE plc are $−0.0600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of ANGLE plc (ANPCF)?
The return on equity (ROE) of ANGLE plc is −87.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ANGLE plc (ANPCF)?
On an EBIT basis the return on assets of ANGLE plc is −49.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ANGLE plc (ANPCF)?
The operating margin of ANGLE plc is −1,216% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ANGLE plc (ANPCF)?
Revenue at ANGLE plc is growing −23.0% versus a year earlier (3y avg +41.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does ANGLE plc (ANPCF) generate?
The free cash flow of ANGLE plc is −£13.9M (fiscal year 2024). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does ANGLE plc (ANPCF) hold?
ANGLE plc holds more cash than debt, £26.9M net (fiscal year 2022). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch ANGLE plc in the live analysis
One click puts ANGLE plc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026